Syenza News

Stay ahead with the latest in HEOR, Global Market Access, health policy, innovative tech, and groundbreaking research. Brought to you by @Syenza_Corp

[Syenza News @SyenzaNews]

🔍 Can comparative effectiveness research (CER) make drug pricing fairer and more evidence-driven?
This article explains how integrating CER into pricing frameworks can align prices with real-world value.

Read the full article: https://t.co/Af9NW7VSbi

[Syenza News @SyenzaNews]

Are formulary changes finally widening access to GLP‑1 therapies? 💊📈
Recent formulary updates are expanding payer coverage and easing utilization controls for GLP‑1 medications ...

Read the full article: https://t.co/gZwIw0RbxI

[Syenza News @SyenzaNews]

Could an implanted brain-computer interface restore movement for people with spinal cord injuries? 🧠 A recent regulatory approval for an invasive BCI ....

Read the full article: https://t.co/HyiYe5JSJB

#SyenzaNews #MedTech #medicaldevices #innovation #healthcarepolicy

[Syenza News @SyenzaNews]

South African health suppliers face mounting compliance pressures under the 2026 Preferential Procurement Regulations. 📋

https://t.co/oHrvb6ugRs

[Syenza News @SyenzaNews]

New post: Advancing Subcutaneous Diuretic Therapy for Heart Failure...

Could subcutaneous diuretic therapy keep heart failure patients out of hospital? 💡

Read more: https://t.co/FCqPtfb3MX

[Syenza News @SyenzaNews]

New post: Advancing Supply Chain Resilience in Europe’s Off-Patent ...

Concerned about recurring shortages of off‑patent medicines in Europe? 🛡️💊

Read more: https://t.co/bOKPJX6QHF

[Syenza News @SyenzaNews]

Can CEE close the East–West healthcare investment gap? 📈🌍 This analysis pinpoints the causes. Read more: https://t.co/iWkREQ42CE

[Syenza News @SyenzaNews]

Advancing Access: Generic Dapagliflozin Approval. 💊📉Read more: https://t.co/OD0osMwLOc

[Syenza News @SyenzaNews]

Can the FDA’s Accelerated Approval pathway deliver faster access without compromising evidence ... Read more: https://t.co/krVk6PyHsj

[Syenza News @SyenzaNews]

🔍 Do amyloid‑beta drugs meaningfully slow Alzheimer’s — or do harms and costs outweigh the modest gains. Read more: https://t.co/Wyari2KHzE

[Syenza News @SyenzaNews]

New Danish study: no link between prenatal acetaminophen and autism — what does this mean? 💊🔎Read more: https://t.co/LfIbCe1b12

[Syenza News @SyenzaNews]

Can community-led, low-cost interventions close the hypertension gap in underserved populations? 🩺🌍
Read more: https://t.co/jqZlgcE55t

[Syenza News @SyenzaNews]

New post: Could strategic partnerships be the key to widening access to long‑acting lenacapavir for HIV preven Read more: https://t.co/PDPwmKTYrA

[Syenza News @SyenzaNews]

New post: Antimicrobial Resistance Art. What happens when art meets antimicrobial resistance? 🎨🔬
Read more: https://t.co/xx0ktnGNKY

[Syenza News @SyenzaNews]

Can pharma-led community programs help close global health gaps? 🌍🤝 Novartis is expanding ... Read more: https://t.co/DrJfa1jkK1

[Syenza News @SyenzaNews]

New post: Advancements in Pulsed Field Ablation,
Varipulse Pro — newly launched. Read more: https://t.co/W4dnSRwmIr

[Syenza News @SyenzaNews]

What does Portugal’s pediatric vaccination policy shift mean for children, clinicians, and public health? Read more: https://t.co/EvdUFVM2G1

[Syenza News @SyenzaNews]

Can robust analytical comparability unlock faster, safer biosimilar approvals? 🔬Read more: https://t.co/jGxBJeSomf

[Syenza News @SyenzaNews]

New post. How would capping insulin copays reshape access to care — and Medicare’s bottom line? 💊Read more: https://t.co/duEp8NmRjM

[Syenza News @SyenzaNews]

Could WVE‑007 be the next breakthrough in targeting visceral fat? Read more: https://t.co/Do6nneJANB